Kolon TissueGene

At a glance

Kolon TissueGene filed 55 disclosures in the last 12 months, including 6 insider, 5 5% holder and 1 issuance. The most recent key filing was on Sep 18: A major holder's stake fell from 65.79% to 65.51% (related-party change).

Revenue for 2025 was ₩3.6M, down 2.5% on 2024. It made an operating loss of ₩15.7M. Debt was 562% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩1.5M and operating loss of ₩8.5M.

The 2025 annual report lists 58 employees with an average tenure of 3.3 years and average pay of ₩163.1M, #24 of 2,191 listed companies by average pay. Its 5 directors and auditors were paid ₩191.7M each on average. It paid no cash dividend for 2025. 코오롱 and related parties held 66.22% at year end.

Of 5 recent 5%+ holder reports, 1 raised and 3 cut a stake; the largest stake reported was 65.99% on Mar 27.

From the 2025 annual report

Staff: 58 (35 men, 23 women), of whom 4 on fixed-term contracts. Total pay for the year: ₩9.6B. Directors and auditors: 5, paid ₩958.3M in total.

No cash dividend was paid for 2025.

Largest shareholder

코오롱 holds 39.27%; with 19 related parties the group holds 66.22% of common shares at year end (from 66.93% at the start of the year).

Individuals paid ₩500M or more

Auditor: 서현회계법인 · opinion: Unqualified.

Rankings: Average pay #24 of 2,191

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports